TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 21)

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 MARKET SCOPE

1.3.1 MARKETS COVERED

1.3.2 YEARS CONSIDERED FOR THE STUDY

1.4 CURRENCY USED FOR THE STUDY

1.5 MAJOR MARKET STAKEHOLDERS

2 RESEARCH METHODOLOGY (Page No. - 24)

2.1 RESEARCH DATA

2.1.1 SECONDARY DATA

2.1.1.1 Secondary sources

2.1.2 PRIMARY DATA

2.2 MARKET ESTIMATION METHODOLOGY

2.2.1 REVENUE MAPPING-BASED MARKET ESTIMATION

2.2.2 PROCEDURE-BASED MARKET ESTIMATION

2.2.3 PRIMARY RESEARCH VALIDATION

2.3 DATA TRIANGULATION

2.4 RESEARCH ASSUMPTIONS

2.5 RESEARCH LIMITATIONS

3 EXECUTIVE SUMMARY (Page No. - 33)

4 PREMIUM INSIGHTS (Page No. - 37)

4.1 HLA TYPING FOR TRANSPLANTS MARKET OVERVIEW

4.2 HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY

4.3 REGIONAL ANALYSIS: HLA TYPING FOR TRANSPLANTS MARKET, BY APPLICATION

4.4 ASIA PACIFIC: HLA TYPING FOR TRANSPLANTS MARKET, BY END USER, 2019

4.5 REGIONAL ANALYSIS: HLA TYPING FOR TRANSPLANTS MARKET, BY PRODUCT & SERVICE

4.6 HLA TYPING FOR TRANSPLANTS MARKET, BY COUNTRY

5 MARKET OVERVIEW (Page No. - 43)

5.1 INTRODUCTION

5.2 MARKET DYNAMICS

5.2.1 KEY MARKET DRIVERS

5.2.1.1 Increasing number of transplant procedures

5.2.1.2 Technological advancements in the field of HLA typing

5.2.1.3 Increasing public-private funding for target research activities

5.2.2 KEY MARKET RESTRAINTS

5.2.2.1 High costs of molecular tests used for HLA typing procedures

5.2.2.2 Limited reimbursements for target procedures

5.2.3 KEY MARKET OPPORTUNITIES

5.2.3.1 Rising adoption of cross-matching and chimerism testing during pre- & post-transplantation

5.2.3.2 Technological shift from non-molecular serological assays to gene-based HLA profiling

5.2.3.3 Increasing public awareness about organ donation and transplantation across emerging countries

5.2.4 KEY MARKET CHALLENGES

5.2.4.1 Significant gap between the number of organ donors and organs required annually

6 HLA TYPING FOR TRANSPLANTS MARKET, BY PRODUCT & SERVICE (Page No. - 50)

6.1 INTRODUCTION

6.2 REAGENTS & CONSUMABLES

6.2.1 INCREASING PATIENT EMPHASIS ON EFFECTIVE PATIENT PROFILING DURING ORGAN TRANSPLANTATION TO DRIVE MARKET GROWTH

6.3 INSTRUMENTS

6.3.1 INCREASING PATIENT AWARENESS ABOUT THE BENEFITS OFFERED BY GENOME-BASED PROFILING WILL SUPPORT MARKET GROWTH

6.4 SOFTWARE & SERVICES

6.4.1 RISING DEMAND FOR INNOVATIVE HLA TYPING SOFTWARE DURING THE DETECTION OF SPECIFIC ALLELES IS SUPPORTING MARKET GROWTH

7 HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY (Page No. - 55)

7.1 INTRODUCTION

7.2 MOLECULAR ASSAY TECHNOLOGIES

7.2.1 PCR-BASED MOLECULAR ASSAYS

7.2.1.1 Sequence-specific oligonucleotide-PCR

7.2.1.1.1 Growing awareness about the benefits offered by SSO-PCR among medical professionals to drive market growth

7.2.1.2 Sequence-specific primer-PCR

7.2.1.2.1 Growing public-private investments for research activities to support market growth

7.2.1.3 Real-time PCR

7.2.1.3.1 High cost of real-time PCR and procedural complexity to hamper market growth

7.2.1.4 Other PCR-based molecular assays

7.2.2 SEQUENCING-BASED MOLECULAR ASSAYS

7.2.2.1 Sanger sequencing

7.2.2.1.1 Growing demand for high-throughput DNA sequencers to drive market growth

7.2.2.2 Next-generation sequencing

7.2.2.2.1 Expansion in the application horizons of NGS in the field of tissue typing to support market growth

7.2.2.3 Other sequencing-based molecular assays

7.3 NON-MOLECULAR ASSAY TECHNOLOGIES

7.3.1 REPLACEMENT OF NON-MOLECULAR ASSAY TECHNIQUES WITH DNA-BASED HLA TYPING PROCEDURES IS EXPECTED TO HAMPER MARKET GROWTH

8 HLA TYPING FOR TRANSPLANTS MARKET, BY APPLICATION (Page No. - 73)

8.1 INTRODUCTION

8.2 DIAGNOSTIC APPLICATIONS

8.2.1 ANTIBODY SCREENING

8.2.1.1 Rising number of recipients for transplant procedures to drive market growth

8.2.2 CHIMERISM MONITORING

8.2.2.1 Rising trend of personalized transplant medicine for effective post-procedural clinical risk management to drive market growth

8.2.3 OTHER APPLICATIONS

8.3 RESEARCH APPLICATIONS

8.3.1 INCREASING IDENTIFICATION OF NEW GENES & BIOMARKERS IN DONOR-RECIPIENT CROSS MATCH WILL DRIVE THE MARKET GROWTH

9 HLA TYPING FOR TRANSPLANTS MARKET, BY END USER (Page No. - 79)

9.1 INTRODUCTION

9.2 INDEPENDENT REFERENCE LABORATORIES

9.2.1 INCREASING NUMBER OF PREVENTIVE GENOMIC CLINICS TO DRIVE MARKET GROWTH

9.3 HOSPITALS & TRANSPLANT CENTERS

9.3.1 HEALTHCARE CONSOLIDATION AND ESTABLISHMENT OF NEW HOSPITALS TO SUPPORT MARKET GROWTH

9.4 RESEARCH LABORATORIES & ACADEMIC INSTITUTES

9.4.1 GROWING AWARENESS ABOUT THE RESEARCH APPLICATIONS IN TRANSPLANT REJECTION MONITORING TO DRIVE MARKET GROWTH

10 HLA TYPING FOR TRANSPLANTS MARKET, BY REGION (Page No. - 84)

10.1 INTRODUCTION

10.2 NORTH AMERICA

10.2.1 US

10.2.1.1 Ongoing technological advancements in the field of HLA typing to drive market growth in the US

10.2.2 CANADA

10.2.2.1 Growing availability of HLA typing products to support market growth in Canada

10.3 EUROPE

10.3.1 GERMANY

10.3.1.1 Germany accounted for the largest share of the European market

10.3.2 UK

10.3.2.1 Rising number of transplantation procedures to drive market growth in the UK

10.3.3 FRANCE

10.3.3.1 Adoption of molecular diagnostic techniques for donor-recipient compatibility testing is increasing in France

10.3.4 ITALY

10.3.4.1 Sluggish growth in the Italian healthcare sector in the last few years to restrain market growth

10.3.5 SPAIN

10.3.5.1 Rising number of solid organ transplantation procedures to drive market growth in Spain

10.3.6 REST OF EUROPE

10.4 ASIA PACIFIC

10.4.1 JAPAN

10.4.1.1 Significant growth in chronic disease prevalence to support market growth in Japan

10.4.2 CHINA

10.4.2.1 Healthcare infrastructure improvements to support market growth in China

10.4.3 INDIA

10.4.3.1 Increasing number of transplantation procedures to drive market growth in India

10.4.4 AUSTRALIA

10.4.4.1 Rising number of solid organ transplantation procedures to support market growth in Australia

10.4.5 SOUTH KOREA

10.4.5.1 Government initiatives to introduce medical coverage for transplantation to support market growth in South Korea

10.4.6 REST OF ASIA PACIFIC

10.5 LATIN AMERICA

10.5.1 BRAZIL

10.5.1.1 Brazil accounted for the largest share of the LATAM market

10.5.2 MEXICO

10.5.2.1 Rising medical tourism to support market growth in Mexico

10.5.3 REST OF LATIN AMERICA

10.6 MIDDLE EAST AND AFRICA

11 COMPETITIVE LANDSCAPE (Page No. - 130)

11.1 OVERVIEW

11.2 MARKET SHARE ANALYSIS

11.3 COMPETITIVE SCENARIO

11.3.1 KEY PRODUCT LAUNCHES AND APPROVALS

11.3.2 KEY AGREEMENTS AND COLLABORATIONS

11.3.3 KEY ACQUISITIONS

11.3.4 KEY EXPANSIONS

11.4 COMPETITIVE LEADERSHIP MAPPING

11.4.1 VISIONARY LEADERS

11.4.2 INNOVATORS

11.4.3 DYNAMIC DIFFERENTIATORS

11.4.4 EMERGING COMPANIES

12 COMPANY PROFILES (Page No. - 136)

12.1 THERMO FISHER SCIENTIFIC

12.1.1 BUSINESS OVERVIEW

12.1.2 PRODUCTS OFFERED

12.1.3 RECENT DEVELOPMENTS (2015�2019)

12.1.4 RECENT DEVELOPMENTS (2015�2019)

12.2 F. HOFFMAN-LA ROCHE LIMITED

12.2.1 BUSINESS OVERVIEW

12.2.2 PRODUCTS OFFERED

12.3 QIAGEN

12.3.1 BUSINESS OVERVIEW

12.3.2 PRODUCTS OFFERED

12.3.3 RECENT DEVELOPMENTS (2015�2019)

12.3.4 MNM VIEW

12.4 IMMUCOR

12.4.1 BUSINESS OVERVIEW

12.4.2 PRODUCTS OFFERED

12.4.3 RECENT DEVELOPMENTS (2015�2019)

12.5 ABBOTT LABORATORIES INC.

12.5.1 BUSINESS OVERVIEW

12.5.2 PRODUCTS OFFERED

12.6 CAREDX, INC.

12.6.1 BUSINESS OVERVIEW

12.6.2 PRODUCTS OFFERED

12.6.3 RECENT DEVELOPMENTS (2016�2019)

12.7 ILLUMINA

12.7.1 BUSINESS OVERVIEW

12.7.2 PRODUCTS & SERVICES OFFERED

12.7.3 RECENT DEVELOPMENTS (2015�2019)

12.7.4 MNM VIEW

12.8 BIO-RAD LABORATORIES

12.8.1 BUSINESS OVERVIEW

12.8.2 PRODUCTS OFFERED

12.9 ALPHA BIOTECH, LTD.

12.9.1 BUSINESS OVERVIEW

12.9.2 PRODUCTS OFFERED

12.10 GENDX

12.10.1 BUSINESS OVERVIEW

12.10.2 PRODUCTS & SERVICES OFFERED

12.10.3 RECENT DEVELOPMENTS (2015�2019)

12.11 LUMINEX

12.11.1 BUSINESS OVERVIEW

12.11.2 PRODUCTS OFFERED

12.11.3 RECENT DEVELOPMENTS (2015�2019)

12.12 BIOFORTUNA

12.12.1 BUSINESS OVERVIEW

12.12.2 PRODUCTS OFFERED

12.12.3 RECENT DEVELOPMENTS (2015�2019)

12.13 OMIXON

12.13.1 BUSINESS OVERVIEW

12.13.2 PRODUCTS OFFERED

12.13.3 RECENT DEVELOPMENTS (2015�2019)

12.14 CREATIVE BIOLABS

12.14.1 BUSINESS OVERVIEW

12.14.2 PRODUCTS OFFERED

12.15 TBG DIAGNOSTICS LIMITED

12.15.1 BUSINESS OVERVIEW

12.15.2 PRODUCTS OFFERED

12.15.3 RECENT DEVELOPMENTS (2015�2019)

12.16 OTHER COMPANIES

12.16.1 BAG HEALTHCARE

12.16.2 TAKARA BIO

12.16.3 HISTOGENETICS LLC

12.16.4 PACIFIC BIOSCIENCES OF CALIFORNIA, INC.

12.16.5 HANSA BIOPHARMA AB

13 APPENDIX (Page No. - 180)

13.1 DISCUSSION GUIDE

13.2 KNOWLEDGE STORE: MARKETSANDMARKETS� SUBSCRIPTION PORTAL

13.3 AVAILABLE CUSTOMIZATIONS

13.4 RELATED REPORTS

13.5 AUTHOR DETAILS



LIST OF TABLES (141 Tables)

TABLE 1 PUBLIC-PRIVATE INVESTMENTS AND RESEARCH GRANTS FOR THE DEVELOPMENT OF HLA TYPING PRODUCTS FOR TRANSPLANT PROCEDURES, 2015�2018

TABLE 2 COST OF ASSAYS FOR MAJOR NGS/PCR-BASED GENOMIC TESTS IN EUROPE (AS OF 2017)

TABLE 3 APPLICABLE CODES FOR HLA TYPING

TABLE 4 HLA TYPING FOR TRANSPLANTS MARKET, BY PRODUCT & SERVICE, 2017�2025 (USD MILLION)

TABLE 5 REAGENTS & CONSUMABLES MARKET, BY REGION, 2017�2025 (USD MILLION)

TABLE 6 INSTRUMENTS MARKET, BY REGION, 2017�2025 (USD MILLION)

TABLE 7 SOFTWARE & SERVICES MARKET, BY REGION, 2017�2025 (USD MILLION)

TABLE 8 HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2017�2025 (USD MILLION)

TABLE 9 MOLECULAR ASSAY TECHNOLOGIES MARKET, BY TYPE, 2017�2025 (USD MILLION)

TABLE 10 MOLECULAR ASSAY TECHNOLOGIES MARKET, BY PRODUCT, 2017�2025 (USD MILLION)

TABLE 11 MOLECULAR ASSAY TECHNOLOGIES MARKET, BY APPLICATION, 2017�2025 (USD MILLION)

TABLE 12 MOLECULAR ASSAY TECHNOLOGIES MARKET, BY END USER, 2017�2025 (USD MILLION)

TABLE 13 MOLECULAR ASSAY TECHNOLOGIES MARKET, BY REGION, 2017�2025 (USD MILLION)

TABLE 14 PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017�2025 (USD MILLION)

TABLE 15 PCR-BASED MOLECULAR ASSAYS MARKET, BY PRODUCT, 2017�2025 (USD MILLION)

TABLE 16 PCR-BASED MOLECULAR ASSAYS MARKET, BY APPLICATION, 2017�2025 (USD MILLION)

TABLE 17 PCR-BASED MOLECULAR ASSAYS MARKET, BY END USER, 2017�2025 (USD MILLION)

TABLE 18 PCR-BASED MOLECULAR ASSAYS MARKET, BY REGION, 2017�2025 (USD MILLION)

TABLE 19 SEQUENCE-SPECIFIC OLIGONUCLEOTIDE-PCR MARKET, BY REGION, 2017�2025 (USD MILLION)

TABLE 20 SEQUENCE-SPECIFIC PRIMER-PCR MARKET, BY REGION, 2017�2025 (USD MILLION)

TABLE 21 REAL-TIME PCR MARKET, BY REGION, 2017�2025 (USD MILLION)

TABLE 22 OTHER PCR-BASED MOLECULAR ASSAYS MARKET, BY REGION, 2017�2025 (USD MILLION)

TABLE 23 SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017�2025 (USD MILLION)

TABLE 24 SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY PRODUCT, 2017�2025 (USD MILLION)

TABLE 25 SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY APPLICATION, 2017�2025 (USD MILLION)

TABLE 26 SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY END USER, 2017�2025 (USD MILLION)

TABLE 27 SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY REGION, 2017�2025 (USD MILLION)

TABLE 28 SANGER SEQUENCING MARKET, BY REGION, 2017�2025 (USD MILLION)

TABLE 29 NEXT-GENERATION SEQUENCING MARKET, BY REGION, 2017�2025 (USD MILLION)

TABLE 30 OTHER SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY REGION, 2017�2025 (USD MILLION)

TABLE 31 NON-MOLECULAR ASSAY TECHNOLOGIES MARKET, BY PRODUCT, 2017�2025 (USD MILLION)

TABLE 32 NON-MOLECULAR ASSAY TECHNOLOGIES MARKET, BY APPLICATION, 2017�2025 (USD MILLION)

TABLE 33 NON-MOLECULAR ASSAY TECHNOLOGIES MARKET, BY END USER, 2017�2025 (USD MILLION)

TABLE 34 NON-MOLECULAR ASSAY TECHNOLOGIES MARKET, BY REGION, 2017�2025 (USD MILLION)

TABLE 35 HLA TYPING FOR TRANSPLANTS MARKET, BY APPLICATION, 2017�2025 (USD MILLION)

TABLE 36 DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2017�2025 (USD MILLION)

TABLE 37 DIAGNOSTIC APPLICATIONS MARKET, BY REGION, 2017�2025 (USD MILLION)

TABLE 38 ANTIBODY SCREENING MARKET, BY REGION, 2017�2025 (USD MILLION)

TABLE 39 CHIMERISM MONITORING MARKET, BY REGION, 2017�2025 (USD MILLION)

TABLE 40 OTHER DIAGNOSTIC APPLICATIONS MARKET, BY REGION, 2017�2025 (USD MILLION)

TABLE 41 RESEARCH APPLICATIONS MARKET, BY REGION, 2017�2025 (USD MILLION)

TABLE 42 HLA TYPING FOR TRANSPLANTS MARKET, BY END USER, 2017�2025 (USD MILLION)

TABLE 43 INDEPENDENT REFERENCE LABORATORIES MARKET, BY REGION, 2017�2025 (USD MILLION)

TABLE 44 HOSPITALS & TRANSPLANT CENTERS MARKET, BY REGION, 2017�2025 (USD MILLION)

TABLE 45 RESEARCH LABORATORIES & ACADEMIC INSTITUTES MARKET, BY REGION, 2017�2025 (USD MILLION)

TABLE 46 HLA TYPING FOR TRANSPLANTS MARKET, BY REGION, 2017�2025 (USD MILLION)

TABLE 47 NORTH AMERICA: HLA TYPING FOR TRANSPLANTS MARKET, BY COUNTRY, 2017�2025 (USD MILLION)

TABLE 48 NORTH AMERICA: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2017�2025 (USD MILLION)

TABLE 49 NORTH AMERICA: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017�2025 (USD MILLION)

TABLE 50 NORTH AMERICA: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017�2025 (USD MILLION)

TABLE 51 NORTH AMERICA: HLA TYPING FOR TRANSPLANTS MARKET, BY PRODUCT & SERVICE, 2017�2025 (USD MILLION)

TABLE 52 NORTH AMERICA: HLA TYPING FOR TRANSPLANTS MARKET, BY APPLICATION, 2017�2025 (USD MILLION)

TABLE 53 NORTH AMERICA: HLA TYPING FOR TRANSPLANTS MARKET, BY END USER, 2017�2025 (USD MILLION)

TABLE 54 US: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2017�2025 (USD MILLION)

TABLE 55 US: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017�2025 (USD MILLION)

TABLE 56 US: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017�2025 (USD MILLION)

TABLE 57 CANADA: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2017�2025 (USD MILLION)

TABLE 58 CANADA: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017�2025 (USD MILLION)

TABLE 59 CANADA: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017�2025 (USD MILLION)

TABLE 60 EUROPE: HLA TYPING FOR TRANSPLANTS MARKET, BY COUNTRY, 2017�2025 (USD MILLION)

TABLE 61 EUROPE: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2017�2025 (USD MILLION)

TABLE 62 EUROPE: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017�2025 (USD MILLION)

TABLE 63 EUROPE: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017�2025 (USD MILLION)

TABLE 64 EUROPE: HLA TYPING FOR TRANSPLANTS MARKET, BY PRODUCT & SERVICE, 2017�2025 (USD MILLION)

TABLE 65 EUROPE: HLA TYPING FOR TRANSPLANTS MARKET, BY APPLICATION, 2017�2025 (USD MILLION)

TABLE 66 EUROPE: HLA TYPING FOR TRANSPLANTS MARKET, BY END USER, 2017�2025 (USD MILLION)

TABLE 67 NO. OF ORGAN TRANSPLANTATION PROCEDURES PERFORMED IN GERMANY, 2015 VS. 2018

TABLE 68 GERMANY: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2017�2025 (USD MILLION)

TABLE 69 GERMANY: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017�2025 (USD MILLION)

TABLE 70 GERMANY: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017�2025 (USD MILLION)

TABLE 71 NO. OF ORGAN TRANSPLANTATION PROCEDURES PERFORMED IN THE UK, 2015 VS. 2018

TABLE 72 UK: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2017�2025 (USD MILLION)

TABLE 73 UK: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017�2025 (USD MILLION)

TABLE 74 UK: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017�2025 (USD MILLION)

TABLE 75 NO. OF ORGAN TRANSPLANTATION PROCEDURES PERFORMED IN FRANCE, 2015 VS. 2018

TABLE 76 FRANCE: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2017�2025 (USD MILLION)

TABLE 77 FRANCE: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017�2025 (USD MILLION)

TABLE 78 FRANCE: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017�2025 (USD MILLION)

TABLE 79 NO. OF ORGAN TRANSPLANTATION PROCEDURES PERFORMED IN ITALY, 2015 VS. 2018

TABLE 80 ITALY: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2017�2025 (USD MILLION)

TABLE 81 ITALY: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017�2025 (USD MILLION)

TABLE 82 ITALY: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017�2025 (USD MILLION)

TABLE 83 NO. OF ORGAN TRANSPLANTATION PROCEDURES PERFORMED IN SPAIN, 2015 VS. 2018

TABLE 84 SPAIN: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2017�2025 (USD MILLION)

TABLE 85 SPAIN: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017�2025 (USD MILLION)

TABLE 86 SPAIN: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017�2025 (USD MILLION)

TABLE 87 ROE: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2017�2025 (USD MILLION)

TABLE 88 ROE: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017�2025 (USD MILLION)

TABLE 89 ROE: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017�2025 (USD MILLION)

TABLE 90 ASIA PACIFIC: HLA TYPING FOR TRANSPLANTS MARKET, BY COUNTRY, 2017�2025 (USD MILLION)

TABLE 91 ASIA PACIFIC: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2017�2025 (USD MILLION)

TABLE 92 ASIA PACIFIC: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017�2025 (USD MILLION)

TABLE 93 ASIA PACIFIC: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017�2025 (USD MILLION)

TABLE 94 ASIA PACIFIC: HLA TYPING FOR TRANSPLANTS MARKET, BY PRODUCT & SERVICE, 2017�2025 (USD MILLION)

TABLE 95 ASIA PACIFIC: HLA TYPING FOR TRANSPLANTS MARKET, BY APPLICATION, 2017�2025 (USD MILLION)

TABLE 96 ASIA PACIFIC: HLA TYPING FOR TRANSPLANTS MARKET, BY END USER, 2017�2025 (USD MILLION)

TABLE 97 JAPAN: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2017�2025 (USD MILLION)

TABLE 98 JAPAN: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017�2025 (USD MILLION)

TABLE 99 JAPAN: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017�2025 (USD MILLION)

TABLE 100 NUMBER OF ORGAN TRANSPLANTATION PROCEDURES PERFORMED IN CHINA, 2013 VS. 2015

TABLE 101 CHINA: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2017�2025 (USD MILLION)

TABLE 102 CHINA: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017�2025 (USD MILLION)

TABLE 103 CHINA: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017�2025 (USD MILLION)

TABLE 104 NO. OF ORGAN TRANSPLANTATION PROCEDURES PERFORMED IN INDIA, 2015 VS. 2018

TABLE 105 INDIA: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2017�2025 (USD MILLION)

TABLE 106 INDIA: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017�2025 (USD MILLION)

TABLE 107 INDIA: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017�2025 (USD MILLION)

TABLE 108 NO. OF ORGAN TRANSPLANTATION PROCEDURES PERFORMED IN AUSTRALIA, 2015 VS. 2018

TABLE 109 AUSTRALIA: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2017�2025 (USD MILLION)

TABLE 110 AUSTRALIA: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017�2025 (USD MILLION)

TABLE 111 AUSTRALIA: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017�2025 (USD MILLION)

TABLE 112 SOUTH KOREA: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2017�2025 (USD MILLION)

TABLE 113 SOUTH KOREA: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017�2025 (USD MILLION)

TABLE 114 SOUTH KOREA: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017�2025 (USD MILLION)

TABLE 115 ROAPAC: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2017�2025 (USD MILLION)

TABLE 116 ROAPAC: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017�2025 (USD MILLION)

TABLE 117 ROAPAC: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017�2025 (USD MILLION)

TABLE 118 LATAM: HLA TYPING FOR TRANSPLANTS MARKET, BY COUNTRY, 2017�2025 (USD MILLION)

TABLE 119 LATAM: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2017�2025 (USD MILLION)

TABLE 120 LATAM: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017�2025 (USD MILLION)

TABLE 121 LATAM: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017�2025 (USD MILLION)

TABLE 122 LATAM: HLA TYPING FOR TRANSPLANTS MARKET, BY PRODUCT & SERVICE, 2017�2025 (USD MILLION)

TABLE 123 LATAM: HLA TYPING FOR TRANSPLANTS MARKET, BY APPLICATION, 2017�2025 (USD MILLION)

TABLE 124 LATAM: HLA TYPING FOR TRANSPLANTS MARKET, BY END USER, 2017�2025 (USD MILLION)

TABLE 125 NO. OF ORGAN TRANSPLANTATION PROCEDURES PERFORMED IN BRAZIL, 2015 VS. 2018

TABLE 126 BRAZIL: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2017�2025 (USD MILLION)

TABLE 127 BRAZIL: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017�2025 (USD MILLION)

TABLE 128 BRAZIL: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017�2025 (USD MILLION)

TABLE 129 NO. OF ORGAN TRANSPLANTATION PROCEDURES PERFORMED IN MEXICO, 2015 VS. 2018

TABLE 130 MEXICO: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2017�2025 (USD MILLION)

TABLE 131 MEXICO: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017�2025 (USD MILLION)

TABLE 132 MEXICO: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017�2025 (USD MILLION)

TABLE 133 ROLATAM: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2017�2025 (USD MILLION)

TABLE 134 ROLATAM: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017�2025 (USD MILLION)

TABLE 135 ROLATAM: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017�2025 (USD MILLION)

TABLE 136 MEA: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2017�2025 (USD MILLION)

TABLE 137 MEA: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017�2025 (USD MILLION)

TABLE 138 MEA: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2017�2025 (USD MILLION)

TABLE 139 MEA: HLA TYPING FOR TRANSPLANTS MARKET, BY PRODUCT & SERVICE, 2017�2025 (USD MILLION)

TABLE 140 MEA: HLA TYPING FOR TRANSPLANTS MARKET, BY APPLICATION, 2017�2025 (USD MILLION)

TABLE 141 MEA: HLA TYPING FOR TRANSPLANTS MARKET, BY END USER, 2017�2025 (USD MILLION)



LIST OF FIGURES (36 Figures)

FIGURE 1 RESEARCH DESIGN

FIGURE 2 BREAKDOWN OF PRIMARIES: GLOBAL HLA TYPING FOR TRANSPLANTS MARKET

FIGURE 3 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING

FIGURE 4 MARKET SIZE ESTIMATION: HLA TYPING FOR TRANSPLANTS MARKET

FIGURE 5 DATA TRIANGULATION METHODOLOGY

FIGURE 6 HLA TYPING FOR TRANSPLANTS MARKET SHARE, BY PRODUCT & SERVICE, 2019 VS. 2025

FIGURE 7 HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2019 VS. 2025 (USD MILLION)

FIGURE 8 HLA TYPING FOR TRANSPLANTS MARKET, BY APPLICATION, 2019 VS. 2025 (USD MILLION)

FIGURE 9 HLA TYPING FOR TRANSPLANTS MARKET, BY END USER, 2019 VS. 2025 (USD MILLION)

FIGURE 10 GEOGRAPHICAL SNAPSHOT OF THE HLA TYPING FOR TRANSPLANTS MARKET

FIGURE 11 INCREASING NUMBER OF TRANSPLANTATION PROCEDURES TO DRIVE MARKET GROWTH DURING THE FORECAST PERIOD

FIGURE 12 PCR-BASED MOLECULAR ASSAYS TO DOMINATE THE MARKET DURING THE FORECAST PERIOD

FIGURE 13 ANTIBODY SCREENING AND CHIMERISM MONITORING SEGMENTS TO WITNESS HIGH GROWTH IN THE ASIA PACIFIC MARKET

FIGURE 14 INDEPENDENT REFERENCE LABORATORIES ARE THE LARGEST END USERS IN THE APAC MARKET

FIGURE 15 NORTH AMERICA IS ESTIMATED TO BE THE LARGEST MARKET FOR ALL PRODUCT & SERVICE SEGMENTS IN THE HLA TYPING FOR TRANSPLANTS MARKET IN 2019

FIGURE 16 MARKET IN CHINA AND INDIA TO WITNESS THE HIGHEST GROWTH DURING THE FORECAST PERIOD

FIGURE 17 HLA TYPING FOR TRANSPLANTS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES

FIGURE 18 NORTH AMERICA: HLA TYPING FOR TRANSPLANTS MARKET SNAPSHOT

FIGURE 19 SOLID ORGAN TRANSPLANTATIONS PERFORMED IN THE US, 2015�2019

FIGURE 20 SOLID ORGAN TRANSPLANTATION PROCEDURES PERFORMED IN CANADA, 2015�2018

FIGURE 21 EUROPE: HLA TYPING FOR TRANSPLANTS MARKET SNAPSHOT

FIGURE 22 ASIA PACIFIC: HLA TYPING FOR TRANSPLANTS MARKET SNAPSHOT

FIGURE 23 NUMBER OF SOLID ORGAN TRANSPLANTATION PROCEDURES PERFORMED IN JAPAN, 2015�2018

FIGURE 24 PRODUCT LAUNCHES AND ENHANCEMENTS WERE THE KEY GROWTH STRATEGIES ADOPTED BY MARKET PLAYERS FROM 2016 TO 2019

FIGURE 25 THERMO FISHER SCIENTIFIC DOMINATES THE GLOBAL HLA TYPING FOR TRANSPLANTS MARKET, AS OF 2019

FIGURE 26 HLA TYPING FOR TRANSPLANTS MARKET (GLOBAL): COMPETITIVE LEADERSHIP MAPPING, 2019

FIGURE 27 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2018)

FIGURE 28 F. HOFFMAN-LA ROCHE LIMITED: COMPANY SNAPSHOT (2018)

FIGURE 29 QIAGEN: COMPANY SNAPSHOT (2018)

FIGURE 30 IMMUCOR: COMPANY SNAPSHOT (2016)

FIGURE 31 ABBOTT LABORATORIES INC.: COMPANY SNAPSHOT (2018)

FIGURE 32 CAREDX: COMPANY SNAPSHOT (2018)

FIGURE 33 ILLUMINA: COMPANY SNAPSHOT (2018)

FIGURE 34 BIO-RAD LABORATORIES: COMPANY SNAPSHOT (2018)

FIGURE 35 LUMINEX: COMPANY SNAPSHOT (2018)

FIGURE 36 TBG DIAGNOSTICS LIMITED: COMPANY SNAPSHOT (2018)